GlobeNewswire Inc | Jun 7, 2021 12:00PM EDT

June 07, 2021

Sanofi launches its new global employee share ownership plan

PARIS - June 7, 2021 - Sanofi today launches Action 2021, its global employeeshare ownership plan, open to 92,000 employees in 73 countries. The program,similar to programs carried out since 2013, clearly demonstrates the ongoingcommitment of Sanofi and its Board of Directors to involve all employees,across all its territories, in the future development and results of thecompany.

"The record level of employee participation in last year?s share plan demonstrated our employee?s commitment to the company and our long-termstrategy and growth. With the continued support of the Board of Directors, wewant our employees to have these opportunities to be increasingly involved inSanofi's success by sharing in its performance," said Paul Hudson, ChiefExecutive Officer of Sanofi.

As of today, the shares will be offered at a subscription price of 69,38?,which is equal to a 20% discount off the average of the 20 opening prices ofSanofi shares from May 6 to June 2, 2021. In addition, for every five sharessubscribed, employees will be able to receive one free share (up to a maximumof four free shares per employee). And finally, each employee will be able topurchase up to 1,500 Sanofi shares within the legal limit of a maximum paymentamount that does not exceed 25% of their gross annual salary, minus anyvoluntary deductions already made under employee savings schemes (Group SavingsPlan and/or Group Retirement Savings Plan) during the year 2021.

In 2020, the employee share ownership plan, open to around 90,000 employees in72 countries, saw its overall uptake rate exceed 36%. More than 33,000 Sanofiemployees chose to invest in the company.

Today, nearly 90,000 current or former employees of the company are direct orindirect shareholders of Sanofi, and hold approximately 2.8% of its capital.

Detailed conditionsAn eligibility condition of three months employment by the closing date of theoffer period will apply. Eligible staff will be able to subscribe shares from 7June 2021 (inclusive) to 25 June 2021 (inclusive). The issue is expected to becompleted and the delivery of the securities carried out by the end of July2021.The maximum number of Sanofi shares that may be issued under this offer is6,294,858 shares (corresponding to a maximum capital increase of ?12,589,717 atnominal value, being 0.5% of share capital)The new shares, including the matching shares (the "Shares"), will besubscribed (or delivered) either directly or through the intermediary ofemployee mutual funds ("FCPE"), depending on the regulations and/or tax regimeapplicable in the various countries of residence of those eligible for thecapital increase.

The Shares will be fully fungible with the existing ordinary shares comprisingthe share capital of Sanofi and will acquire dividend rights as from 1 January2021.The voting rights attached to the subscribed Shares will be exercised directlyby the employees.Those taking up this offer will be required to hold the Shares or thecorresponding FCPE units for a period of approximately five years, i.e. until31 May 2026, except upon the occurrence of an early release event provided forunder Article R. 3324-22 of the French Labour Code and authorized in thesubscriber's country.Admission of the Shares to trading on the Euronext Paris market (ISIN Code:FR0000120578 ) on the same line as the existing shares will be requested assoon as possible after the completion of the capital increase.This press release does not constitute an offer to sell or a solicitation tobuy Sanofi shares. The offer of Sanofi shares reserved for employees will onlybe made in countries where such an offer has been registered with or notifiedto the competent local authorities and/or following the approval of aprospectus by the competent local authorities, or in consideration of anexemption from the requirement to prepare a prospectus or to register or notifyof the offer, where such procedure is required.More generally, the offer will only be made in countries where all requiredregistration and/or notification procedures have been carried out, approvalsobtained, and procedures for consulting or informing employee representativesfollowed.This press release is not intended for and should not be copied to ordistributed in countries where such a prospectus has not been approved or suchexemption is not available or where all necessary registration, notification,consultation and/or information procedures have not been completed orauthorisations obtained. This relates in particular to Cameroon, Japan and thePhilippines, where to date formalities are still pending with the authoritiesbut could also relate to other countries.

This press release is prepared in accordance with the exemption frompublication of a prospectus under Article 1 4i) and 5h) of the ProspectusRegulation (EU) 2017/1129. It constitutes the document required to meet theconditions for exemption from publication of a prospectus as defined by theProspectus Regulation.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life



Media Relations Contacts Investor Relations Contacts ParisAshleigh Koss Eva Schaefer-JansenTel: +1 (908) 205-2572 Arnaud DelepineAshleigh.Koss@sanofi.com Nathalie Pham



Sandrine Guendoul Investor Relations Contacts North AmericaTel.: +33 (0)6 25 09 14 25 Felix LauscherMR@sanofi.com Fara Berkowitz Suzanne Greco

Nicolas KressmannTel.: +1 (732) 532-5318 IR main line:Nicolas.Kressmann@sanofi.com Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.com



Attachment

-- PDF